← Browse by Condition
Medical Condition

alk gene mutation

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for alk gene mutation sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — alk gene mutation Clinical Trials

How many clinical trials are currently recruiting for alk gene mutation?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for alk gene mutation, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for alk gene mutation?
alk gene mutation research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a alk gene mutation clinical trial?
Eligibility criteria for alk gene mutation trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
University of Colorado, Denver 1 trial
Hunan Province Tumor Hospital 1 trial

Recruiting Clinical Trials

NCT03042221
Recruiting
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
Enrollment
100 pts
Location
United States
Sponsor
University of Colorado, Denver
View Trial →
NCT05266846 Phase 2
Recruiting
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Enrollment
78 pts
Location
China
Sponsor
Hunan Province Tumor Hospital
View Trial →

Related Conditions

non small cell carcinoma of lung tnm stage 4 (1) non small cell lung cancer (1) egfr gene mutation (1) rose cluster 1 (1) braf v600e (1) lung adenocarcinoma (1) immunotherapy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology